The global AI in biotechnology market size is calculated at USD 3.89 billion in 2025 and is expected to reach around USD 18.76 billion by 2034, growing at a CAGR of 19.04% for the forecasted period.
Ottawa, Nov. 19, 2025 (GLOBE NEWSWIRE) — The global AI in biotechnology market size was valued at USD 3.27 billion in 2024 and is predicted to hit around USD 18.76 billion by 2034, rising at a 19.04% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research. The global AI in biotechnology market is driven by the expanding healthcare applications and growing innovations.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/6312
Key Takeaways
- North America held a major revenue of 50% share of the market in 2024.
- Asia Pacific is expected to witness the fastest growth in the AI in biotechnology market during the forecast period.
- By primary application/use case, the drug discovery & lead generation segment held a major revenue of approximately 36% share of the market in 2024.
- By primary application/use case, the agriculture/industrial biotech applications segment is expected to witness the fastest growth in the market during the forecast period.
- By core AI technology, the classical ML/Deep learning models segment held a major revenue of approximately 30% share of the market.
- By core AI technology, the generative AI segment is expected to witness the fastest growth in the market during the forecast period.
- By commercial model, the SaaS/cloud AI platforms segment held a major revenue of approximately 48% share of the market in 2024 and is expected to witness the fastest growth in the market during the forecast period.
- By end user/buyer type, the large pharma & big biotech segment held a major revenue of approximately 52% share of the market in 2024.
- By end user/buyer type, the biotech startups & virtual biotechs segment is expected to witness the fastest growth in the market during the forecast period.
What is the AI in Biotechnology?
The AI in biotechnology is driven by an explosion of biological data, an urgent need to accelerate drug discovery, and a shift towards precision medicine. The AI in biotechnology refers to the use of artificial intelligence technologies to discover, design, and optimize biological solutions more efficiently and rapidly than traditional methods in the biotech sector.
Key Indicators and Highlights
| Table | Scope | |
| Market Size in 2025 | USD 3.89 Billion | |
| Projected Market Size in 2034 | USD 19.04 Billion | |
| CAGR (2025 – 2034) | 18.76 | % |
| Leading Region | North America by 50% | |
| Market Segmentation | By Primary Application / Use Case, By Core AI Technology, By Commercial Model, By End User / Buyer Type, By Region | |
| Top Key Players | Exscientia , Recursion Pharmaceuticals, Insilico Medicine, Atomwise, BenevolentAI, Schrödinger, Deep Genomics, Valo Health, Cyclica / Numinus, Relay Therapeutics, NVIDIA, Microsoft / Azure, Alphabet / DeepMind, IQVIA, Certara, Evotec, Charles River / Labcorp, Atomwise, Benchling / Collaborative data platforms, Startups & aggregators | |
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
What are the Major Growth Drivers in the AI in Biotechnology Market?
The growing advancements in AI technologies act as the major driver in the market. This is increasing the development of various models, solutions, and tools, which are enhancing drug development and diagnostic approaches. Moreover, increasing investments, demand for personalized medicines, and increasing accessibility to cloud and SaaS platforms are the other market drivers.
What are the Key Drifts in the AI in Biotechnology Market?
The market has been expanding due to the growing funding to launch and enhance the use of various AI solutions.
- In November 2025, a total of $100 million was secured by Busy Iambic Therapeutics, which will be utilized to advance its AI-discovered therapeutics portfolio.
- In November 2025, to advance the clinical use of AI-driven brain health biomarkers and expand the neurodiagnostic dataset, a total of $86 million raised in the Series B funding round will be utilized by Beacon Biosignals.
- In July 2025, $2.8 million in pre-seed funding was secured by Algocell, which is an Israeli startup focused on AI-driven bioprocess optimization. To accelerate the scale-up and efficiency of cell-based manufacturing, this funding will be used to advance its platform.
What is the Significant Challenge in the AI in Biotechnology Market?
Data privacy concerns act as a major challenge in the market. These platforms handle sensitive patient or clinical data, where their breaches can lead to decreased use, so they must comply with the strict regulatory standards. Additionally, high implementation cost, limited quality data, skilled personnel shortage, and regulatory challenges are other market restraints.
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
Regional Analysis
Why did North America Dominate the AI in Biotechnology Market in 2024?
In 2024, North America captured the biggest revenue share of 50% in the market, due to the presence of large biotech companies, which heavily invested in AI solutions. Moreover, the growing generation of biomedical data has also increased its demand. Additionally, the companies contributed to their increased innovation, launches, adoption, and use in the R&D, which enhanced the market growth.
What Made the Asia Pacific Show the Fastest Growth in the AI in Biotechnology Market in 2024?
Asia Pacific is expected to host the fastest growth in the market during the forecast period, due to expanding biotech and pharmaceutical industries. The growing diseases and investments have increased their use for the evaluation of the datasets and precision medicine development. Additionally, their affordability increased their adoption by startups, where new partnerships were also formed to enhance their use in R&D activities, promoting the market growth.
Segmental Insights
By primary application/use case analysis
Why Did the Drug Discovery & Lead Generation Segment Dominate in the AI in Biotechnology Market in 2024?
By primary application/use case, the drug discovery & lead generation segment led the market with approximately 36% share in 2024, due to its faster experiments. It was used to evaluate a vast amount of chemical libraries with accuracy and identify ADME properties, which increased their use in various R&D processes.
By primary application/use case, the agriculture/industrial biotech applications segment is expected to show the highest growth during the predicted time, driven by increasing food demands. The growing climatic changes and government initiatives are increasing their use during innovations and sustainable biomanufacturing.
Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
By core AI technology analysis
Which Core AI Technology Type Segment Held the Dominating Share of the AI in Biotechnology Market in 2024?
By core AI technology, the classical ML/deep learning models segment held the dominating share of approximately 30% in the market, driven by its compatibility, accuracy, and performance in various imaging, sequencing, and chemical data. This increased their use in genomics, proteomics, activity prediction, etc.
By core AI technology, the generative AI segment is expected to show the fastest growth rate during the predicted time, due to its ability to develop new drug candidates. This accelerates the R&D, which is increasing their use in the development of new models, backed by investments.
By commercial model analysis
What Made SaaS/Cloud AI Platforms the Dominant Segment in the AI in Biotechnology Market in 2024?
By commercial model, the SaaS/cloud AI platforms segment led the market with approximately 48% share in 2024 and is expected to show the highest growth during the upcoming years, due to their ability to handle massive datasets and lower upfront cost. Moreover, their easy integration and high performance enhanced their use in R&D activities, where their security updates helped in protecting the data.
By end-user/buyer type analysis
How did the Large Pharma & Big Biotech Segment Dominated the AI in Biotechnology Market in 2024?
By end user/buyer type, the large pharma & big biotech segment held the dominating share of approximately 52% of the market in 2024, driven by their high R&D activities and investments. This increased the use of AI technologies to accelerate drug discovery and development by reducing the operational cost, which led to new collaborations to leverage their capabilities.
By end user/buyer type, the biotech startups & virtual biotechs segment is expected to show the fastest growth rate during the upcoming years, due to their affordability and minimal infrastructure requirements. They are being used to accelerate the R&D, where the outsourcing trends are also promoting their use.
Browse More Insights of Towards Healthcare:
The global AI in magnetic imaging (MRI) market is forecasted to expand from USD 6.13 billion in 2024 to USD 11.22 billion by 2034, growing at a CAGR of 6.23% from 2025 to 2034.
The global AI in oncology market size is estimated at US$ 1.95 billion in 2024 and is projected to grow to US$ 2.52 billion in 2025, reaching around US$ 25.02 billion by 2034. The market is projected to expand at a CAGR of 29.36% between 2025 and 2034.
The global AI in cancer diagnostics market size is calculated at USD 1.07 billion in 2024 and is expected to be worth USD 2.61 billion by 2034, expanding at a CAGR of 9.35% from 2024 to 2034.
The global AI in dental market size is estimated at US$ 459.6 million in 2024, is projected to grow to US$ 559.2 million in 2025, and is expected to reach around US$ 3263.9 million by 2034. The market is projected to expand at a CAGR of 21.78% between 2025 and 2034.
The global AI in Lab Automation market is emerging as a high-growth sector, projected to witness substantial revenue expansion throughout the forecast period from 2024 to 2034.
The AI in biopharmaceuticals market size is calculated at US$ 1.55 billion in 2024, grew to US$ 2.05 billion in 2025, and is projected to reach around US$ 24.49 billion by 2034. The market is expanding at a CAGR of 32.27% between 2025 and 2034.
The global AI in medical devices market size is calculated at US$ 22.29 billion in 2024, grew to US$ 32.21 billion in 2025, and is projected to reach around US$ 886.39 billion by 2034. The market is expanding at a CAGR of 44.53% between 2025 and 2034.
The AI in genomics market size is forecast to grow at a CAGR of 23.6%, from USD 1.67 billion in 2025 to USD 11.26 billion by 2034, over the forecast period from 2025 to 2034.
The global AI in wound care market size is calculated at USD 0.64 in 2024, grew to USD 0.86 billion in 2025, and is projected to reach around USD 12.9 billion by 2034. The market is expanding at a CAGR of 35.03% between 2025 and 2034.
The global AI in medical coding market size is expected to grow from USD 2.98 billion in 2025 to USD 9.16 billion by 2034, with a CAGR of 13.3% throughout the forecast period from 2025 to 2034.
Recent Developments in the AI in Biotechnology Market
- In November 2025, to discover novel therapeutics with the use of the Pharma.AI platform of Insilico Medicine, a collaboration between Insilico Medicine and Eli Lilly was announced.
- In June 2025, the U.S.-India Innovation Bridge for next-gen innovation and R&D focusing on AI, biotech, startup ecosystems, and quantum, was launched in Bengaluru.
AI in Biotechnology Market Key Players List
- Insilico Medicine
- Exscientia
- Atomwise
- Recursion Pharmaceuticals
- Deep Genomics
- BenevolentAI
- Valo Health
- Schrodinger
- NVIDIA
- Cyclica/Numinus
- Microsoft/Azure
- Relay Therapeutics
- Alphabet/DeepMind
- Evotec
- IQVIA
- Startups & aggregators
- Certara
- Atomwise
- Charles River/Labcorp
- Benchling/Collaborative data platforms
Segments Covered in The Report
By Primary Application/Use Case
- Drug discovery & lead generation
- Preclinical research & biomarker discovery
- Clinical development & trial optimization
- Bioprocessing & manufacturing optimization (PAT, yield, QC)
- Diagnostics & companion-diagnostics (AI for image/omics readouts)
- Agriculture/industrial biotech applications
By Core AI Technology
- Classical ML/Deep Learning models
- Graph Neural Networks (molecular GNNs)
- Generative AI
- NLP / Knowledge graphs for literature & IP mining
- Digital twins & physics-hybrid models
- Explainable AI/uncertainty quantification
By Commercial Model
- SaaS/Cloud AI platforms
- (platform subscriptions, API access)
- Collaborative partnerships/discovery alliances (shared milestones) Fee-for-service (project CRO style engagements)
- Licensed on-prem deployments (large pharma)
- Model & dataset licensing/marketplaces
By End User/Buyer Type
- Large Pharma & Big Biotech
- Biotech Startups & Virtual Biotechs
- CROs / CDMOs using AI internally
- Academic & translational research centers
- Diagnostics / Agri-bio companies
By Region
North America
- U.S.
- Canada
- Mexico
- Rest of North America
South America
- Brazil
- Argentina
- Rest of South America
Europe
- Western Europe
- Germany
- Italy
- France
- Netherlands
- Spain
- Portugal
- Belgium
- Ireland
- UK
- Iceland
- Switzerland
- Poland
- Rest of Western Europe
- Eastern Europe
- Austria
- Russia & Belarus
- Türkiye
- Albania
- Rest of Eastern Europe
Asia Pacific
- China
- Taiwan
- India
- Japan
- Australia and New Zealand,
- ASEAN Countries (Singapore, Malaysia)
- South Korea
- Rest of APAC
MEA
- GCC Countries
- Saudi Arabia
- United Arab Emirates (UAE)
- Qatar
- Kuwait
- Oman
- Bahrain
- South Africa
- Egypt
- Rest of MEA
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/6312
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web: https://www.towardshealthcare.com
Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.